Saquinavir indications and usage

Jump to navigation Jump to search
Saquinavir
INVIRASE ® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]

Indications And Usage

INVIRASE in combination with ritonavir and other antiretroviral agents is indicated for the treatment of HIV-1 infection in adults (over the age of 16 years).

The following points should be considered when initiating therapy with INVIRASE:

  • The twice daily administration of INVIRASE in combination with ritonavir is supported by safety data from the MaxCmin 1 trial [see Adverse Reactions (6.1)] and pharmacokinetic data [see Clinical Pharmacology ].
  • The efficacy of INVIRASE with ritonavir has not been compared against the efficacy of antiretroviral regimens currently considered standard of care.
  • The number of baseline primary protease inhibitor mutations affects the virologic response to INVIRASE/ritonavir[1]


References

  1. "INVIRASE (SAQUINAVIR MESYLATE) CAPSULE INVIRASE (SAQUINAVIR MESYLATE) TABLET, FILM COATED [GENENTECH, INC.]".

Adapted from the FDA Package Insert.